Cargando…

Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia

Resistance to chemotherapy is one of the primary obstacles in acute myeloid leukemia (AML) therapy. Micro-RNA-23a (miR-23a) is frequently deregulated in AML and has been linked to chemoresistance in solid cancers. We, therefore, studied its role in chemoresistance to cytarabine (AraC), which forms t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hatzl, Stefan, Perfler, Bianca, Wurm, Sonja, Uhl, Barbara, Quehenberger, Franz, Ebner, Susanne, Troppmair, Jakob, Reinisch, Andreas, Wölfler, Albert, Sill, Heinz, Zebisch, Armin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072365/ https://www.ncbi.nlm.nih.gov/pubmed/32093419 http://dx.doi.org/10.3390/cancers12020496

Ejemplares similares

Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs
por: Zebisch, Armin, et al.
Publicado: (2016)

EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity
por: Berg, Johannes Lorenz, et al.
Publicado: (2021)

Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia
por: Berg, Johannes Lorenz, et al.
Publicado: (2021)

High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34‐positive AML
por: Daga, Shruti, et al.
Publicado: (2019)

Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis
por: Caraffini, Veronica, et al.
Publicado: (2020)

Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry‐based leukemic cell enrichment followed by mutational profiling
por: Daga, Shruti, et al.
Publicado: (2020)

RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis
por: Zebisch, Armin, et al.
Publicado: (2019)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
por: Prochazka, Katharina T., et al.
Publicado: (2019)

Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing
por: Kashofer, Karl, et al.
Publicado: (2017)

TNFα Rescues Dendritic Cell Development in Hematopoietic Stem and Progenitor Cells Lacking C/EBPα
por: Anirudh, Subramanian, et al.
Publicado: (2020)

Detection of AML-specific TP53 mutations in bone marrow–derived mesenchymal stromal cells cultured under hypoxia conditions
por: Müller, Marian, et al.
Publicado: (2019)

BRAF(V600E) promotes DC3/monocyte differentiation in human gene-engineered HSPCs and causes multisystem histiocytosis
por: Sconocchia, Tommaso, et al.
Publicado: (2023)

Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation
por: Milewska, Malgorzata, et al.
Publicado: (2015)

Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities
por: Foßelteder, Johannes, et al.
Publicado: (2023)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model
por: Pabst, Gabriel, et al.
Publicado: (2020)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
por: Momparler, Richard L
Publicado: (2013)

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia
por: Jost, Felix, et al.
Publicado: (2019)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance
por: Åbacka, Hannah, et al.
Publicado: (2021)

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
por: Anderson, Rebecca, et al.
Publicado: (2022)

Acute myeloid leukemia with severe coagulation disorder and concomitant central nervous system bleeding – a clinical diagnostic case report
por: Hatzl, S., et al.
Publicado: (2018)

Feasibility and safety of using an automated decision support system for insulin therapy in the treatment of steroid‐induced hyperglycemia in patients with acute graft‐versus‐host disease: A randomized trial
por: Aberer, Felix, et al.
Publicado: (2018)

Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia
por: Wang, Jing, et al.
Publicado: (2013)

Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia
por: Leonard, Sarah M., et al.
Publicado: (2014)

Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
por: Bashir, Yasir, et al.
Publicado: (2015)

Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells
por: Li, Peng, et al.
Publicado: (2016)

Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota
por: Liu, Junmin, et al.
Publicado: (2022)

Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia
por: Khokhlatchev, Andrei V., et al.
Publicado: (2022)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia
por: Sun, Huali, et al.
Publicado: (2023)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia
por: Geissler, Klaus, et al.
Publicado: (2020)

Auricular Oedema and Dyshidrotic Eczema in a Patient with Acute Myeloid Leukaemia Treated with Cytarabine
por: Brandt, K., et al.
Publicado: (2010)

Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon
por: Rodrigues, Amanda Lopes Maia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j15b9fi6ffo40qpimqg8o57dab